ELI LILLY & Co
For the period ended Dec 31, 2023. Filed Feb 21, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Feb 21, 2024
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Part II
Item 5. Market for the Registrant's Common Equity, Related Stockholder Matters, and Issuer Purchases of Equity Securities
Information relating to the principal market for our common stock, dividends, and related stockholder matters is described in Item 7, "Management's Discussion and Analysis of Results of Operations and Financial Condition" and Item 12, "Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters." This information is incorporated herein by reference.
As of February 16, 2024, there were approximately 18,871 holders of record of our common stock based on information provided by EQ Shareowner Services, our transfer agent. Our common stock is listed under the ticker symbol LLY on the New York Stock Exchange (NYSE).
The following table summarizes the activity related to repurchases of our equity securities during the fourth quarter ended December 31, 2023:
| Period | Total Number ofShares Purchased(in thousands) | Average Price Paidper Share | Total Number of SharesPurchased as Part ofPublicly AnnouncedPlans or Programs(in thousands) | Approximate Dollar Valueof Shares that May Yet BePurchased Under thePlans or Programs(dollars in millions) |
|---|---|---|---|---|
| October 2023 | — | $— | — | $2,500.0 |
| November 2023 | — | — | — | 2,500.0 |
| December 2023 | — | — | — | 2,500.0 |
| Total | — | — | — |
During the three months ended December 31, 2023, we did not repurchase any shares under our $5.00 billion share repurchase program authorized in May 2021.
PERFORMANCE GRAPH
The following graph compares the return on Lilly stock with that of the Standard & Poor's (S&P) 500 Stock Index and our peer group for the years 2019 through 2023. The graph assumes that, on the last business day of 2018, a person invested $100 each in Lilly stock, the S&P 500 Stock Index, and the peer group's collective common stock. The graph measures total shareholder return, which takes into account both stock price and dividends. It assumes that dividends paid by a company are immediately reinvested in that company's stock.
Value of $100 Invested on Last Business Day of 2018 Comparison of Five-Year Cumulative Total Shareholder Return Among Lilly, S&P 500 Stock Index, and Peer Group(1)
| Lilly | Peer Group | S&P 500 | |
|---|---|---|---|
| Dec-18 | $100.00 | $100.00 | $100.00 |
| Dec-19 | 116.15 | 118.31 | 131.49 |
| Dec-20 | 152.23 | 121.00 | 155.68 |
| Dec-21 | 252.82 | 145.23 | 200.37 |
| Dec-22 | 339.38 | 158.70 | 164.08 |
| Dec-23 | 546.08 | 158.45 | 207.21 |
(1)We constructed the peer group as the industry index for this graph. It is comprised of the following companies in the pharmaceutical and biotechnology industries: AbbVie Inc.; Amgen Inc.; AstraZeneca PLC; Biogen Inc.; Bristol-Myers Squibb Company; Gilead Sciences Inc.; GlaxoSmithKline plc; Johnson & Johnson; Merck & Co., Inc.; Novartis AG; Novo Nordisk A/S; Pfizer Inc.; Roche Holding AG; Sanofi S.A.; and Takeda Pharmaceutical Company Limited. The peer group used for performance benchmarking aligns with the peer group used for executive compensation purposes for 2023.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.